Chester County News and Community Website
BERWYN, PA — AscellaHealth has released its latest edition of the Specialty & Rare Pipeline Digest™. This quarterly digital publication stands as the industry’s most detailed resource on imminent specialty …
AscellaHealth Unveils Quarter’s Insights on Specialty and Rare Disease Drug Developments Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) recently announced financial results for the fourth quarter and full year ended December 31, 2023. The company also provided an update on …
FDA Clearance Paves Way for Aprea Therapeutics’ Next-Gen Cancer Drug, APR-1051 to Enter Phase 1 Clinical Trial Read More BERWYN, PA — AscellaHealth announced that CEO and President Belazi was invited to participate on a panel during the recent 2023 annual meeting of the Self Insurance Institute of America …
AscellaHealth President and CEO Dea Belazi Delivers Impactful Discussion at 2023 SIIA Annual Meeting Read More
The global custom antibody market is a rapidly expanding sector of the pharmaceutical and biotechnology industries. According to Transparency Market Research (TMR), the market, valued at $442.3 million in 2023, …
The Global Custom Antibody Market: A Comprehensive Analysis Read More
PHILADELPHIA, PA — Mispro is set to open a full-service vivarium facility in Philadelphia’s thriving UCity biocluster in January 2024.
Mispro to Open Contract Vivarium in Philadelphia’s UCity Biocluster Read More
With psoriasis impacting over 8 million Americans, the continual search for improved treatments is essential. Fortunately, a recent study from Spherix Global Insights, the Chester County-based market research company for …
The Future of Plaque Psoriasis Treatment: A Shift Towards Oral Medication Read More BERWYN, PA — AscellaHealth recently released its Q2 2023 Specialty & Rare Pipeline Digest™, the industry’s most comprehensive resource on new, pending and projected Specialty and Rare Disease drug launches, …
AscellaHealth Releases Q2 2023 Specialty & Rare Pipeline Digest Read More
WAYNE, PA — Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, recently announced the planned pivotal Phase 3 study design of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), a topical mTOR …
Palvella Therapeutics Announces Planned Pivotal Phase 3 Study Design of QTORIN 3.9% Rapamycin Anhydrous Gel Read More WAYNE, PA — Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, recently announced topline results from VAPAUS, a 24-week, randomized, double-blind, placebo-controlled pivotal Phase 3 study of QTORIN™ 3.9% rapamycin anhydrous …
Palvella Therapeutics Reports Topline Results from Pivotal Phase 3 VAPAUS Study of QTORIN 3.9% Rapamycin Anhydrous Gel Read More
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company, this week announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) …
Trevena Regains Compliance with Nasdaq Listing, Reaffirms Expected Near-Term Milestones Read More